Cancer anorexia-cachexia syndrome: Cytokines and neuropeptides

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 7, Issue 4, 2004, Pages 427-434

  Ramos, Eduardo J B ^a   Suzuki, Susumu ^a   Marks, Daniel ^b   Inui, Akio ^c   Asakawa, Akihiro ^c   Meguid, Michael M ^a,d  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b Oregon and Sciences University ^*  (United States)

^c KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d University Hospital   (United States)

Author keywords

Anorexia; Cachexia; Cytokine; Neuropeptide

Indexed keywords

COCAINE AND AMPHETAMINE REGULATED TRANSCRIPT PEPTIDE; CORTICOTROPIN RELEASING FACTOR; CYTOKINE; GHRELIN; HORMONE; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 6; LEPTIN; MELANOCORTIN; NEUROPEPTIDE; NEUROPEPTIDE Y; TUMOR NECROSIS FACTOR ALPHA; PEPTIDE HORMONE;

ADVANCED CANCER; ANOREXIA; BODY WEIGHT; CACHEXIA; CANCER ANOREXIA CACHEXIA SYNDROME; CLINICAL TRIAL; CYTOKINE PRODUCTION; HUMAN; NONHUMAN; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INDUCTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; ANIMAL; METABOLISM; NEOPLASM; PATHOPHYSIOLOGY; PHYSIOLOGY; SYNDROME;

ANIMALS; ANOREXIA; CACHEXIA; CYTOKINES; HUMANS; LEPTIN; NEOPLASMS; NEUROPEPTIDES; PEPTIDE HORMONES; SYNDROME;

EID: 14844320127     PISSN: 13631950     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mco.0000134363.53782.cb     Document Type: Review

References (84)

1. Mantovani G, Maccio A, Massa E, Madeddu C. Managing cancer-related anorexia/cachexia. Drugs 2001; 61:499-514.
2. Inui A. Cancer anorexia-cachexia syndrome: are neuropeptides the key? Cancer Res 1999; 59:4493-4501.
3. Plata-Salaman CR. Central nervous system mechanisms contributing to the cachexia-anorexia syndrome. Nutrition 2000; 16:1009-1012.
4. Laviano A, Meguid MM, Rossi-Fanelli F. Cancer anorexia: clinical implications, pathogenesis, and therapeutic strategies. Lancet Oncol 2003; 4:686-694. This review article discusses important issues in the management of patients with cancer anorexia and cachexia, including current drug therapy and prospects for future treatment. The article also provides an overview of the use of ω3 polyunsaturated fatty acids in the treatment of anorexia-cachexia syndrome.
5. Inui A. Feeding and body-weight regulation by hypothalamic neuropeptides - mediation of the actions of leptin. Trends Neurosci 1999; 22:62-67.
6. Schwartz MW, Woods SC, Porte D Jr, et al. Central nervous system control of food intake. Nature 2000; 404:661-671.
7. Rubin H. Cancer cachexia: its correlations and causes. Proc Natl Acad Sci USA 2003; 100:5384-5389. In this study the author reevaluates the central role of proteolytically generated peptides derived from tumors in producing cancer cachexia.
8. Inui A. Cytokines and sickness behavior: implications from knockout animal models. Trends Immunol 2001; 22:469-473.
9. Matthys P, Billiau A. Cytokines and cachexia. Nutrition 1997; 13:763-770.
10. Lonnroth C, Moldawer LL, Gelin J, et al. Tumor necrosis factor-alpha and interleukin-1 alpha production in cachectic, tumor-bearing mice. Int J Cancer 1990; 46:889-696.
11. Wisse BE, Frayo RS, Schwartz MW, et al. Reversal of cancer anorexia by blockade of central melanocortin receptors in rats. Endocrinology 2001; 142:3292-3301.
12. Langhans W, Hrupka B. Interleukins and tumor necrosis factor as inhibitors of food intake. Neuropeptides 1999; 33:415-424.
13. Mantovani G, Maccio A, Mura L, et al. Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. J Mol Med 2000; 78:554-561.
14. Turrin NP, Ilyn SE, Gayle D, et al. Interleukin-1β system in anorectic catabolic tumor bearing rats. Cytokine, Neuropeptide and G Protein alpha-subunit mRNAs in Anorectic MCA Tumor Bearing Rats. Curr Opin Clin Nutr 2004; 4:419-426. In this article, the authors evaluated the effects of cancer anorexia in specific components of the cytokine-induced anorectic reactions, including interleukin 1β system components, tumor necrosis factor α, transforming growth factor β1, and interferon γ, in tumor tissue, liver and brain of anorectic rats. The results suggest that the interleukin 1β system plays a significant role in this model of cancer anorexia.
15. Gutierrez EG, Banks WA, Kastin AJ. Murine tumor necrosis factor alpha is transported from blood to brain in the mouse. J Neuroimmunol 1993; 47:169-176.
16. Katafuchi T, Motomura K, Baba S, et al. Differential effects of tumor necrosis factor-α and -β on rat ventromedial hypothalamic neurons in vitro. Am J Physiol 1997; 272:1966-1971.
17. Torelli GF, Meguid MM, Moldawer LL, et al. Use of recombinant human soluble TNF receptor in anorectic tumor-bearing rats. Am J Physiol Regul lntegr Comp Physiol 1999; 277:R850-R855.
18. Argiles JM, Moore-Carrasco R, Busquets S, Lopez-Soriano FJ. Catabolic mediators as targets for cancer cachexia. Drug Disc Today 2003; 8:838-844. This review article evaluates the different molecular mechanisms and catabolic mediators that are involved in cancer cachexia. It discusses the roles of cytokines and potential molecular strategies to fight against anorexia.
19. Plata-Salaman CR. Immunoregulators in the nervous system. Neurosci Biobehav Rev 1991; 15:185-215.
20. Yang ZJ, Blaha V, Meguid MM, et al. Interleukin-1 alpha injection into ventromedial hypothalamic nucleus of normal rats depresses food intake and increases release of dopamine and serotonin. Pharmacol Biochem Behav 1999; 62:61-65.
21. Laviano A, Meguid MM. Serotonin and obesity. Curr Med Chem Central Nervous System Agents 2003; 3:89-100. This article provides a concise overview of the relationship between monoamines and food-intake control.
22. Godbout JP, Johnson RW. Interelukin-6 in the aging brain. J Neuroimmunol 2004; 147:141-144.
23. Strassmann G, Jacob CO, Evans R, et al. Mechanisms of experimental cancer cachexia. Interaction between mononuclear phagocytes and colon-26 carcinoma and its relevance to IL-6-mediated cancer cachexia. J Immunol 1992; 148:3674-3678.
24. Tsujinaka T, Fujita J, Ebisui C, et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in interleukin 6 transgenic mice. J Clin Invest 1996; 97:244-249.
25. Borden EC, Chin P. Interleukin-6: a cytokine with potential diagnostic and therapeutic roles. J Lab Clin Med 1994; 123:824-829.
26. Martin F, Santolaria F, Batista N, et al. Cytokine levels (IL-6 and IFN-gamma), acute phase response and nutritional status as prognostic factors in lung cancer. Cytokine 1999; 11:80-86.
27. Segal MA, Crnic LS. An animal model for the behavioral effects on interferon. Behav Neurosci 1990; 104:612-618.
28. Matthys P, Heremans H, Opdenakker G, Billiau A. Anti-interferon-gamma antibody treatment, growth of Lewis lung tumors in mice and tumor-associated cachexia. Eur J Cancer 1991; 27:182-187.
29. Matthys P, Dijkmans R, Proost P, et al. Severe cachexia in mice inoculated with interferon-gamma-producing tumor cells. Int J Cancer 1991; 49:77-82.
30. Oh WK, Manola J, George DJ, et al. A phase II trial of interferon-alpha and toremifene in advanced renal cell cancer patients. Cancer Invest 2002; 20:186-191.
31. Cummins MJ, Pruitt B. Low-dose oral use of human interferon-alpha in cancer patients. J Interferon Cytokine Res 1999; 19:937-941.
32. Inui A, Meguid MM. Cachexia and obesity: two sides of one coin? Curr Opin Clin Nutr Metab Care 2003; 6:395-399. This paper discusses the orexigenic and anorexigenic circuits that lead to either obesity or cachexia. It discusses the mechanisms by which metabolic signals from periphery lead to an imbalance in the central nervous system, leading to an increase or a decrease in food intake, and the role of leptin in the anorexia-cachexia syndrome.
33. Zigman JM, Elmquist JK. Minireview: From anorexia to obesity - the yin and yang of body weight control. Endocrinology 2003; 144:3749-3756.
34. Sato T, Laviano A, Meguid MM, et al. Involvement of plasma leptin, insulin and free tryptophan in cytokine-induced anorexia. Clin Nutr 2003; 22:139-146. The authors injected interleukin 1α and/or tumor necrosis factor α, or tryptophan subcutaneously into male rats to evaluate their effects on food intake, body weight, carcass adiposity, plasma leptin and insulin. This article provides evidence that interleukin 1α injection decreased food intake and increased plasma free tryptophan that may contribute to synthesis of brain serotonin induced by interleukin 1α.
35. Hahn TM, Breininger JF, Baskin DG, Schwartz MW. Coexpression of AgRP and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1998; 1:271-272.
36. Elias CF, Lee C, Kelly J, et al. Leptin activates hypothalamic CART neurons projecting to the spinal cord. Neuron 1998; 21:1375-1385.
37. Baskin DG, Breininger JF, Schwartz MW. Leptin receptor mRNA identifies a subpopulation of neuropeptide Y neurons activated by fasting in rat hypothalamus. Diabetes 1999; 48:828-833.
38. Cheung CC, Clifton DK, Steiner RA. Proopiomelanocortin neurons are direct targets for leptin in the hypothalamus. Endocrinology 1997; 138:4489-4492.
39. Simons JP, Annenmie MWJ, Schols L, et al. Plasma concentration of total leptin and human lung-cancer-associated cachexia. Clin Sci 1997; 93:273-277.
40. Wallace AM, Naveed S, McMillan DC. Effect of weight loss and the inflammatory response on leptin concentrations in gastrointestinal cancer patients. Clin Cancer Res 1998; 4:2977-2979.
41. Lopez-Soriano J, Carbo N, Tessitore L, et al. Leptin and tumor growth in rats. Int J Cancer 1999; 81:726-729.
42. Aleman MR, Santolaria F, Batista N, et al. Leptin role in advanced lung cancer. A mediator of the acute phase response or a marker of the status of nutrition? Cytokine 2002; 19:21-26.
43. Mantovani G, Madeddu C, Gramignano G, et al. Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters. J Exp Ther Oncol 2003; 3:205-219.
44. Takabatake N, Nakamura H, Abe S, et al. Circulating leptin in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 159:1215-1219.
45. Sato T, Meguid MM, Miyata G, et al. Does leptin really influence cancer anorexia? Nutrition 2002; 18:82-83.
46. Papathanassoglou ED, Moynihan JA, Ackerman MH, Mantzoros CS. Serum leptin levels are higher but are not independently associated with severity or mortality in the multiple organ dysfunction/systemic inflammatory response syndrome: A matched case control and a longitudinal study. Clin Endocrinol 2001; 54:225-233.
47. Moses AG, Dowidar N, Holloway B, et al. Leptin and its relation to weight loss, ob gene expression and the acute-phase response in surgical patients. Br J Surg 2001; 88:588-593.
48. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
49. Asakawa A, Inui A, Kaga T, et al. Ghrelin is an appetite-stimulatory signal from stomach with structural resemblance to motilin. Gastroenterology 2001; 120:337-345.
50. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 2001; 409:194-198.
51. Inui A. Ghrelin: an orexigenic and somatotrophic signal from the stomach. Nat Rev Neurosci 2000; 2:551-560.
52. Inui A, Asakawa A, Bowers CY, et al. Ghrelin, appetite, and gastric motility: the emerging role of the stomach as an endocrine organ. FASEB J 2004; 18:439-456. This article is an overview of the current available data about ghrelin. This article illustrates the importance of ghrelin in regulating food intake and describes the interaction of ghrelin with the hypothalamic food-intake system and with peripheral hormones.
53. Willesen MG, Kristensen P, Romer J. Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 1999; 70:306-316.
54. Kamegai J, Tamura H, Shimizu T, et al. Chronic central infusion of ghrelin increases hypothalamic neuropeptide Y and Agouti-related protein mRNA levels and body weight in rats. Diabetes 2001; 50:2438-2443.
55. Nagaya M, Uematsu M, Kojima M, et al. Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation 2001; 104:1430-1435.
56. Tanaka M, Naruo T, Nagai N, et al. Habitual binge/purge behavior influences circulating ghrelin levels in eating disorders. J Psychiatr Res 2003; 37:17-22.
57. Hanada T, Toshinai K, Date Y, et al. Upregulation of ghrelin expression in cachectic nude mice bearing human melanoma cells. Metabolism 2004; 53:84-88. In this interesting article the authors studied the biosynthesis and secretion of ghrelin in a cancer (melanoma) cachexia mouse model. The plasma concentration of ghrelin increased with the progression of cachexia, providing evidence of the involvement of ghrelin in the regulation of energy homeostasis in cancer anorexia-cachexia syndrome.
58. Hanada T, Toshinai K, Kajimura N, et al. Anti-cachectic effect of ghrelin in nude mice bearing human melanoma cells. Biochem Biophys Res Commun 2003; 301:275-279.
59. Shimizu Y, Nagaya N, Isobe T, et al. Increased plasma ghrelin level in lung cancer cachexia. Clin Cancer Res 2003; 9:774-778.
60. Bona G, Bellone S. Central and peripheral activities of ghrelin, a ligand of the growth hormone secretagogue receptor. Panminerva Med 2003; 45:197-201.
61. Cummings DE, Schwartz MW. Melanocortins and body weight: a tale of two receptors. Nat Genet 2000; 26:8-9.
62. Chen AS, Marsh DJ, Trumbauer ME, et al. Inactivation of the mouse melanocortin-3 receptor results in increased fat mass and reduced lean body mass. Nat Genet 2000; 26:97-102.
63. Hagan MM, Rushing PA, Schwartz MW, et al. Role of the CNS melanocortin system in the response to overfeeding. J Neurosci 1999; 19:2362-2367.
64. Lawrence CB, Rothwell NJ. Anorexic but not pyrogenic actions of interleukin-1 are modulated by central melanocortin-3/4 receptors in the rat. J Neuroendocrinol 2001; 13:490-495.
65. Marks DL, Ling N, Cone RD. Role of the central melanocortin system in cachexia. Cancer Res 2001; 61:1432-1438.
66. Marks DL, Butler AA, Turner R, et al. Differential role of melanocortin receptor subtypes in cachexia. Endocrinology 2003; 144:1513-1523.
67. Woods SC, Seeley RJ, Porte D Jr, Schwartz MW. Signals that regulate food intake and energy homeostasis. Science 1998; 280:1378-1383.
68. Sonti G, Ilyin SE, Rata-Salaman CR. Neuropeptide Y blocks and reverses interleukin-1 beta-induced anorexia in rats. Peptides 1996; 17:517-520.
69. Pu S, Dhillon H, Moldawer LL, et al. Neuropeptide Y counteracts the anorectic and weight reducing effects of ciliary neurotropic factor. J Neuroendocrinol 2000; 12:827-832.
70. Gayle D, Ilyin SE, Plata-Salaman CR. Central nervous system IL-1 beta system and neuropeptide Y mRNAs during IL-1 beta-induced anorexia in rats. Brain Res Bull 1997; 44:311-317.
71. Chance WT, Balasubramaniam A, Dayal R, et al. Hypothalamic concentration and release of neuropeptide Y into microdialysates is reduced in anorectic tumor-bearing rats. Life Sci 1994; 54:1869-1874.
72. Chance WT, Balasubramaniam A, Thompson H, et al. Assessment of feeding response of tumor-bearing rats to hypothalamic injection and infusion of neuropeptide Y. Peptides 1996; 17:797-801.
73. Makarenko IG, Meguid MM, Gatto L, et al. Decreased NPY innervation of the hypothalamic nuclei in rats with cancer anorexia. Brain Res 2003; 961:100-108. This article analyzed the hypothalamic NPY immunostaining in tumor-bearing rats. It provides the overall effects of anorexia on NPY concentration in many hypothalamic regions. Also discussed in detail are the hypothalamic regions involved in food-intake control. This paper supports the theory that at the onset of anorexia in tumor-bearing rats, an altered hypothalamic NPY system influences the food intake.
74. Smagin GN, Dunn AJ. The role of CRF receptor subtypes in stress-induced behavioral responses. Eur J Pharmacol 2000; 405:199-206.
75. Spina M, Merlo-Pich E, Chan RK, et al. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science 1996; 273:1561-1564.
76. Cullen MJ, Ling N, Foster AC, Pelleymounter MA. Urocortin, corticotropin releasing factor-2 receptors and energy balance. Endocrinology 2001; 142:992-999.
77. Contarino A, Dellu F, Koob GF, et al. Dissociation of locomotor activation and suppression of food intake induced by CRF in CRFR1-deficient mice. Endocrinology 2000; 141:2698-2702.
78. Uehara A, Sekiya C, Takasugi Y, et al. Anorexia induced by interleukin 1: involvement of corticotropin-releasing factor. Am J Physiol Regul Integr Comp Physiol 1989; 257:R613-R617.
79. McCarthy HD, McKibbin PE, Perkins AV, et al. Alterations in hypothalamic NPY and CRF in anorexic tumor-bearing rats. Am J Physiol Endocrinol Metab 1993; 264:E638-E643.
80. Dautzenberg FM, Hauger RL. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 2002; 23:71-77.
81. Kristensen P, Judge ME, Thim L, et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 1998; 393:72-76.
82. Willie JT, Chemelli RM, Sinton CM, Yanagisawa M. To eat or to sleep? Orexin in the regulation of feeding and wakefulness. Annu Rev Neurosci 2001; 24:429-458.
83. Shimada M, Tritos NA, Lowell BB, et al. Mice lacking melanin- concentrating hormone are hypophagic and lean. Nature 1998; 396:670-674.
84. Mystkowski P, Seeley RJ, Hahn TM, et al. Hypothalamic melanin-concentrating hormone and estrogen-induced weight loss. J Neurosci 2000; 20:8637-8642.